Skip to content Skip to footer

Datar Cancer Genetics Launches Exacta AI to Offer Personalized Treatment Options for Cancer Patients

Shots: Datar Cancer Genetics has introduced Exacta AI (multi-analyte platform) to provide ~10 evidence-based drug combinations as a treatment for cancer patients who have exhausted SoC options Exacta AI integrates 360° tumor work-up with AI-driven analysis of complex tumor interactome data to assess drug interactions, toxicity, & side effects for ADCs, CPIs, targeted therapies,…

Read more

Light Horse Therapeutics Partners with Novartis to Discover Therapies for Cancer Treatment

Shots: Light Horse has entered into a multi-target partnership with Novartis to discover & develop FIC targets for cancer treatment by using its proprietary chemical libraries & precision genetic editing platform that identifies novel functional domains in disease-critical targets As per the agreement, Light Horse is entitled to receive $25M upfront, $1B research, development…

Read more

Roche

Roche’s Tecentriq Hybreza Receives the US FDA’s Approval for Cancer Treatment 

  Shots:    The US FDA has approved Tecentriq Hybreza (SC) to treat all IV indications, incl. lung, liver, skin & soft tissue cancers. Regulatory reviews across other regions are underway  The approval was supported by P-IB/III (IMscin001) study assessing Tecentriq Hybreza (SC) vs Tecentriq (IV) in locally advanced or metastatic NSCLC patients (n=371) failed on…

Read more

VIEWPOINTS_Moitreyee Chatterjee-Kishore1_Kohei Shitara2_2024

Unlocking Approval: Moitreyee Chatterjee-Kishore from Astellas & Kohei Shitara in Conversation with PharmaShots

Shots:  East Asia and East Europe report significant incidences of Gastric Cancer. In 2022, Japan registered around 44,000 mortalities due to Gastric Cancer  VYLOY, an anti-claudin 18.2 (CLDN18.2) monoclonal antibody, received Japan’s approval in combination with chemotherapy for patients with HER2 -ve, CLDN18.2+ve, unresectable, advanced, or recurrent gastric cancer  Today, at PharmaShots we have Moitreyee…

Read more

VIEWPOINTS_Lev Becker_2024

Onchilles Pharma at AACR 2024: Lev Becker in a Stimulating Conversation with PharmaShots

Shots:  Recently, Onchilles Pharma unveiled findings from the late-stage preclinical data of its two candidates: N17350 and N17465  Today at PharmaShots, we had an engaging dialogue exchange with Lev Becker, Associate Professor, University of Chicago and Cofounder, Onchilles Pharma  Lev highlights the unique novel mechanism that Onchilles Pharma leverages to treat a wide range of…

Read more

Dr. Reddy’s Laboratories Expects the Launch of Versavo (biosimilar, bevacizumab) for the Treatment of Several Cancer Indications Across the UK

Shots:  The company has developed Versavo as a biosimilar of Avastin, approved for the treatment of various cancer indications incl. metastatic colorectal cancer, advanced non-squamous NSCLC, recurrent glioblastoma, mRCC, advanced cervical cancer, ovarian cancer & metastatic breast cancer  Based on the clinical evaluation, Versavo is expected to be approved and launched across the UK as…

Read more

Spotlight Interview_David A. Dodd

Spotlight Interview: David A. Dodd, CEO at GeoVax Labs, in an Engaging Conversation with PharmaShots

PharmaShots’ Spotlight offers a unique platform for biopharma, life sciences, and healthcare companies, allowing them to connect with their target audiences and like-minded people.  This week at the Spotlight, we had a riveting discussion with David A. Dodd, Chairman, President & CEO, at GeoVax Labs.  David eloquently highlighted GeoVax’s extraordinary journey over the years from…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]